Bendamustine Hydrochloride
Bendamustine Hydrochloride is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Bendamustine Hydrochloride; Generic name: BENDAMUSTINE HYDROCHLORIDE; Manufacturer: Apotex Corp.
| Brand name | Bendamustine Hydrochloride |
|---|---|
| Generic name | BENDAMUSTINE HYDROCHLORIDE |
| Manufacturer | Apotex Corp |
| Used for | 1 INDICATIONS AND USAGE Non-Hodgkin Lymphoma (NHL) Bendamustine hydrochloride injection is indicated for the treatment of adult patients with indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine hydrochloride injection is an alkylating drug indicated for treatment of adult patients with: • Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. ( 1 ) |
| Dosage | 2 DOSAGE AND ADMINISTRATION For NHL : • 120 mg/m 2 infused intravenously over 60 minutes on Days 1 and 2 of a 21-day cycle, up to 8 cycles ( 2.1 ) 2.1 Dosing Instructions for NHL Recommended Dosage: The recommended dosage is 120 mg/m 2 administered intravenously over 60 minutes on Days 1 and 2 of a 21-day cycle, up to 8 cycles. Dose Delays, Dosage Modifications and Reinitiation of Therapy for NHL: Delay bendamustine hydrochloride injection administration in the event of a Grade 4 hematologic tox |
| Active ingredient(s) | BENDAMUSTINE HYDROCHLORIDE |
| Route | INTRAVENOUS |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=085dd54c-4212-d879-afef-ee52732a48c0 |